Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QTRX 
Quanterix Corp (QTRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: QTRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.27% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 211.42M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 4 | Beta 1.07 | 52 Weeks Range 4.05 - 15.86 | Updated Date 08/29/2025 |
52 Weeks Range 4.05 - 15.86 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.43 | Actual -0.77 |
Profitability
Profit Margin -56.05% | Operating Margin (TTM) -86.17% |
Management Effectiveness
Return on Assets (TTM) -10.28% | Return on Equity (TTM) -22.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -14218087 | Price to Sales(TTM) 1.68 |
Enterprise Value -14218087 | Price to Sales(TTM) 1.68 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA -1.49 | Shares Outstanding 46465900 | Shares Floating 39871937 |
Shares Outstanding 46465900 | Shares Floating 39871937 | ||
Percent Insiders 6.46 | Percent Institutions 73.41 |
Upturn AI SWOT
Quanterix Corp
Company Overview
History and Background
Quanterix Corp was founded in 2007 and is headquartered in Billerica, Massachusetts. The company focuses on ultra-sensitive biomarker detection for life science research and diagnostics. It's grown through technological advancements and strategic partnerships.
Core Business Areas
- Simoa Technology & Instruments: Quanterix's core is its Single Molecule Array (Simoa) technology, offering ultra-sensitive biomarker detection. This powers their instruments like the HD-X Analyzer and SR-X Ultra-Sensitive Biomarker Detection System.
- Assay Development & Services: The company develops and offers a range of assays for measuring biomarkers in various fields like neurology, immunology, and oncology. They also provide custom assay development services.
- Accelerator Lab Services: Quanterix also offers lab services on a fee-for-service basis, allowing researchers to leverage Simoa technology without purchasing equipment.
Leadership and Structure
Masoud Toloue serves as CEO and Board Chairman. The company has a typical corporate structure with departments like R&D, Sales, Marketing, and Operations.
Top Products and Market Share
Key Offerings
- Simoa HD-X Analyzer: The HD-X Analyzer is Quanterix's flagship instrument, used for quantifying low-abundance proteins in biological samples. Its market share is difficult to pinpoint exactly, but Quanterix is a leader in the ultra-sensitive biomarker detection space. Competitors include companies like Luminex and Meso Scale Discovery (MSD).
- Simoa SR-X Ultra-Sensitive Biomarker Detection System: The SR-X is a benchtop analyzer that brings Simoa technology to a wider range of researchers. Its specific market share is also hard to define but it competes with other benchtop immunoassay analyzers. Competitors include Bio-Rad and Thermo Fisher Scientific.
- Alzheimer's Disease Assays: Quanterix develops and sells assays to measure biomarkers related to Alzheimer's disease. The company is a key player in Alzheimer's biomarker research. Competitors include Roche and other diagnostic companies developing AD tests.
Market Dynamics
Industry Overview
The biomarker detection market is growing, driven by advancements in precision medicine, drug development, and diagnostics. The demand for highly sensitive and accurate biomarker measurements is increasing.
Positioning
Quanterix is positioned as a leader in ultra-sensitive biomarker detection, particularly for low-abundance proteins. Their competitive advantage lies in the Simoa technology's superior sensitivity.
Total Addressable Market (TAM)
The total addressable market (TAM) for precision health technologies, including biomarker analysis, is estimated to reach hundreds of billions of dollars. Quanterix is well-positioned to capture a significant share through continued innovation and market expansion.
Upturn SWOT Analysis
Strengths
- Proprietary Simoa Technology
- Ultra-sensitive biomarker detection capabilities
- Strong presence in neurology and Alzheimer's research
- Established customer base in research and biopharma
Weaknesses
- High cost of instruments and assays
- Limited market penetration compared to larger diagnostic companies
- Reliance on a single core technology (Simoa)
- Variable profitability due to investment in R&D.
Opportunities
- Expansion into new therapeutic areas (e.g., oncology, immunology)
- Development of new assays and applications for Simoa technology
- Strategic partnerships with pharmaceutical companies
- Increased adoption of precision medicine and biomarker-based diagnostics
Threats
- Competition from established diagnostic companies with broader product portfolios
- Technological advancements from competitors
- Regulatory hurdles for new diagnostic assays
- Economic downturn affecting research funding.
Competitors and Market Share
Key Competitors
- Luminex Corp (LMNX)
- Meso Scale Diagnostics (Private)
- Bio-Rad Laboratories (BIO)
- Thermo Fisher Scientific (TMO)
Competitive Landscape
Quanterix has a competitive advantage in ultra-sensitivity but faces competition from larger companies with broader product portfolios. Success depends on innovation and market penetration.
Major Acquisitions
Uman Diagnostics AB
- Year: 2018
- Acquisition Price (USD millions): 20
- Strategic Rationale: Acquired Uman Diagnostics to expand its neurology assay portfolio, especially for neurofilament light chain (NfL) measurement.
Growth Trajectory and Initiatives
Historical Growth: Quanterix has experienced periods of rapid revenue growth, driven by increased adoption of Simoa technology. Growth has been inconsistent, affected by market conditions and operational execution.
Future Projections: Analyst estimates suggest continued revenue growth, driven by expansion into new markets and applications. Profitability is expected to improve over time. Data needed to fill in accurately
Recent Initiatives: Recent initiatives include new assay development, strategic partnerships, and expansion of the Accelerator Lab service.
Summary
Quanterix is a company with strong technology in ultra-sensitive biomarker detection but faces challenges in achieving profitability and competing with larger diagnostic firms. Their Simoa technology gives them a competitive edge, particularly in neurology, but they need to manage costs and expand their market reach. Key opportunities lie in strategic partnerships and developing new applications for their technology. Monitoring the competitive landscape and adapting to market changes will be crucial for their long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Analyst Reports (e.g., Yahoo Finance, Bloomberg), Company Website, Press Releases
- Market Reports (e.g., Grand View Research)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change. Market share values may be estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quanterix Corp
Exchange NASDAQ | Headquaters Billerica, MA, United States | ||
IPO Launch date 2017-12-07 | President, CEO & Director Dr. Masoud Toloue Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 471 | Website https://www.quanterix.com |
Full time employees 471 | Website https://www.quanterix.com | ||
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.